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22 Abstract 
23 Study question: Can the incidence of subsequent termination of pregnancy (TOP) be diminished 
24 by providing intrauterine contraception as part of abortion services?
25 Summary answer: Provision of IUD as part of TOP services reduced the need for subsequent TOP 
26 during 5-year follow-up, butand the effect was limited to the first three years.
27 What is known already: IUD is highly effective in preventing subsequent TOP. Prompt initiation 
28 of IUD leads to higher usage rate during follow-up, as compliance with post-TOP IUD insertion 
29 visits is low.
30 Study design, size, duration: The objective of this randomised controlled trial was to assess the 
31 effect of early comprehensive provision of intrauterine contraception after TOP on the incidence 
32 of subsequent TOP during five years of follow-up.
33 This study was conducted at Helsinki University Hospital between October 18th 2010 and January 
34 21st 2013. Altogether 748 women undergoing a first trimester TOP were recruited and randomised 
35 into two groups. The intervention group (n=375) was provided with an IUD during surgical TOP or 
36 1–4 weeks following medical TOP at the hospital providing the abortion care. Women in the 
37 control group (n=373) were advised to contact primary health care for follow-up and IUD 
38 insertion. Subsequent TOPs during the 5-year follow-up were identified from the Finnish Register 
39 on induced abortions. 
40 Participants, setting, methods: The inclusion criteria were age ≥ 18 years, duration of gestation 
41 ≤12 weeks, residence in Helsinki and accepting intrauterine contraception. Women with 
42 contraindications to IUD were excluded.  
43 Main results and the role of chance: The overall numbers of subsequent TOPs were 50 in the 
44 intervention and 72 in the control group (26.7 vs. 38.6/1000 years of follow-up, p=0.027) and 
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45 those of requested TOPs including TOPS and early pregnancy failures 58 and 76 (30.9 vs. 
46 40.8/1000, p=0.080). Altogether 40 (10.7%) women in the intervention and 63 (16.9%) in the 
47 control group underwent one or several subsequent TOPs (HR 1.67 [CI 95% 1.13 to 2.49], 
48 p=0.011). The number of TOPs was reduced by the intervention during years 0–3 (22.2 vs. 
49 46.5/1000, p=0.035), but not during years 4–5 (33.3 vs. 26.8/1000, p=0.631). 
50 Limitations, reasons for caution: Both medical and surgical TOP were used. This may be seen as 
51 a limitation, but it also reflects the contemporary praxis of abortion care. The immediate post-TOP 
52 care were provided by two different organizations allowing us to compare two different ways of 
53 contraceptive service provision following TOP. 
54 Wider implications of the findings: Providing TOP and IUD insertion comprehensively in a same 
55 heath care unit leads to significantly higher rates of attendance, IUD use and significantly lower 
56 risk of subsequent TOP (HR 1.67 [CI 95% 1.13 to 2.49], p=0.011).
57 Study funding/competing interest(s): This study was supported by Helsinki University Central 
58 Hospital Research funds and by research grants provided by the Jenny and Antti Wihuri 
59 Foundation, the Yrjö Jahnsson Foundation, and Finska Läkaresällskapet. EP has received a personal 
60 research grant from the Finnish Medical Society. The City of Helsinki supported the study by 
61 providing the IUDs. The funding organisations had no role in planning or execution of the study, or 
62 in analysing the study results.
63 Trial registration number: The trial was registered at clinicaltrials.gov (NCT01223521).
64 Trial registration date: 18th October 2010.
65 Date of first patient’s enrolment: 18th October 2010.
66 Keywords: Abortion/termination of pregnancy, IUD/intrauterine contraception, subsequent TOP
67
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68 Ethics approval
69 We received approvals from the Ethics Committee of the Hospital District of Helsinki and Uusimaa 
70 (HUS 260/13/03/03/2009), the Ethics Committee of the City of Helsinki (10-1138/054). Approval to 
71 carry out the study was granted by the Hospital District of Helsinki and Uusimaa (§12/30.03.2010).  
72 The Finnish Institute for Health and Welfare (THL) granted an approval to use personal-level data, 
73 which is required for registry-based studies in Finland (THL/1479/5.05.00/2013). All personal-level 
74 data that could be used to identify individuals was removed before the analyses.
75 Transparency statement
76 The lead author* affirms that this manuscript is an honest, accurate, and transparent account of 
77 the study being reported; that no important aspects of the study have been omitted; and that any 
78 discrepancies from the study as planned (and, if relevant, registered) have been explained.
79 Patient and public information statement
80 The study was initiated in 2009, and at the time it was not customary to involve patients and/or 
81 public in planning of a scientific study.
82 Dissemination declaration
83 The study results will be disseminated to the health care providers and organizations involved in 
84 the study as well as to the public once the study has been published.
85
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89 The efficacy of long-acting reversible contraceptives (LARCs) and, especially, that of intrauterine 
90 devices (IUD) in preventing unwanted pregnancy is well established (Peipert et al., 2012; Winner 
91 et al., 2012; Blumenthal et al., 2011; Secura et al., 2014). According to several recent guidelines, 
92 LARCs have become the recommended method of contraception for women in all age groups 
93 (WHO, 2015; RCOG, 2018).
94 Previous cohort studies have shown that young age, parity, and history of termination of 
95 pregnancy (TOP) are associated with increased risk of subsequent TOP (Heikinheimo et al., 2008). 
96 In addition, contraceptive choices affect the risk of subsequent unwanted pregnancy. In cohort 
97 studies, post-abortal use of IUD has been associated with a 60–70% reduction in the need of 
98 subsequent TOP (Okusanya et al., 2014; Rose et al., 2012). 
99 Regardless of the method of TOP, the resumption of ovarian function occurs rapidly; 80% of 
100 women ovulate within 6 weeks after TOP (Schreiber et al., 2011). In addition, 50% of women 
101 resume sexual activity in two weeks following TOP (Boesen et al., 2004). Thus, in order to prevent 
102 subsequent unwanted pregnancy, immediate initiation of effective contraception is important. In 
103 Finland, contraceptive counselling and planning are routinely included in the TOP process, and 
104 women are advised to initiate contraceptive use immediately. Yet, more than one in three women 
105 undergoing a TOP have a history of one or several previous TOPs.  Similar to several other 
106 countries, this rate has been increasing during the past decade in Finland (THL, 2018; 
107 Socialstyrelsen, 2018; INED, 2012; GOV.UK, 2018).
108 The insertion of IUD at the time of surgical TOP is effective and safe, and results in higher IUD use 
109 during follow-up (Okusanya et al., 2014; WHO, 2012; Sääv et al., 2012; Bednarek et al., 2011). 
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110 However, medical abortion has become the dominant method in several countries during the last 
111 decades (THL, 2018; Socialstyrelsen, 2018; INED, 2012; GOV.UK, 2018). Medical abortion poses 
112 challenges concerning IUD provision since compliance with post-abortion care in the service-
113 delivery systems assessed is often poor (Betstadt et al., 2011; Pohjoranta et al., 2018). Immediate 
114 insertion of an IUD after medical TOP (MTOP) is safe, although it is associated with a higher risk of 
115 partial expulsion (Korjamo et al., 2017). In contrast, IUD provision at approximately one week after 
116 MTOP does not significantly increase the risk of expulsion (Sääv et al., 2012; Shimoni et al., 2011; 
117 Betstadt et al., 2011). As with surgical abortion, the prompt provision of IUD leads to a higher rate 
118 of use and subject satisfaction following MTOP (Sääv et al., 2012).
119 In the present study, we studied the efficacy of routine provision of IUD as part of abortion care in 
120 comparison to the current praxis of prescribing oral contraceptives as a bridging method and 
121 directing women to primary health care (PHC) for IUD insertion. Our primary outcome measure 
122 was the number of subsequent TOPs performed during the 5-year follow-up after the index 
123 abortion. The secondary outcomes were the number of all requested TOPs during the follow-up 
124 (including cases of miscarriage, blighted ovum or ectopic pregnancy) and the timing of subsequent 
125 TOP. Previously, we published the 1-year follow-up results concerning the need for subsequent 
126 TOP, success of early IUD insertion, rates of attendance and IUD use, as well as mental and sexual 
127 well-being (Pohjoranta et al., 2015; Pohjoranta et al., 2017; Pohjoranta et al., 2018; Toffol et al., 
128 2016). In the present study, we report the final 5-year results on the need for subsequent TOP.
129
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130 Methods
131 Study design and participants
132 This study design has been described in detail previously (Pohjoranta et al., 2015). The study was 
133 conducted in collaboration with the Helsinki University Hospital and the City of Helsinki. 
134 The inclusion criteria were age ≥18 years, residence in Helsinki, duration of gestation ≤12+0 weeks, 
135 having a non-foetal indication for the abortion and signing an informed consent form. Women 
136 with uterine anomaly, cervical screening result requiring surgical intervention, or inadequate 
137 language skills in Finnish or Swedish were excluded. Acute liver disease and breast cancer were 
138 contraindications for the levonorgestrel-releasing intrauterine system (LNG-IUS), and copper 
139 allergy, iron deficiency anaemia, and Wilson’s disease for copper intrauterine device (Cu-IUD). The 
140 characteristics of the study participants are presented in Table 1.
141
142 Altogether 751 women were randomised into two groups (Figure 1). Women in the intervention 
143 group (n=375) were provided with an IUD (either the 52mg levonorgestrel-releasing intrauterine 
144 system, LNG-IUS, Mirena® or a Cu-IUD, Nova-T®, both manufactured by Bayer Ag [Turku, Finland] 
145 and hereafter referred as IUD) at the hospital responsible for the abortion care. The IUD was 
146 planned to be inserted at the time of surgical abortion (n=70), or at a follow-up visit performed 1–
147 4 weeks after MTOP (n=305). Women in the control group (n=373 [71 cases of surgical and 302 
148 medical abortion]) were prescribed oral contraceptives and advised to contact their PHC unit for 
149 follow-up and contraceptive services including IUD insertion, according to the current national 
150 guideline on induced abortion (Duodecim, 2013). The subsequent TOPs were analysed on an 
151 intention-to-treat analysis (ITT) to assess the efficacy of the intended intervention.
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152 Procedures
153 All abortions were performed according to the national guideline (Duodecim, 2013). All the index 
154 abortions in this study were performed due to a social indication, or based on the woman’s age of 
155 at least 40 years or having given birth to four or more children, both indications for abortion given 
156 in the Finnish legislation. The participants were advised to contact the hospital in case of 
157 suspected abortion-related adverse events or complications. 
158 According to local guideline of the time, all women were invited for a follow-up at three months 
159 after IUD insertion. For the intervention group, this was performed by study nurse. All women 
160 were provided a follow-up visit by a specialist in obstetrics and gynaecology (SS) at one and five 
161 years at the PHC family planning clinic of the City of Helsinki.  
162 Data on subsequent induced abortions during five years after the index abortion were obtained 
163 from the Finnish Register of Induced Abortions kept by the Finnish Institute for Health and Welfare 
164 (THL). In Finland, reporting all TOPs to THL is mandatory by the law, and thus the coverage of the 
165 register is very high (Heino et al., 2018). These data were complemented with data from the 
166 electronic patient files of the Hospital District of Helsinki and Uusimaa, where also the requested 
167 TOPs later diagnosed as ectopic pregnancies or miscarriages were identified. All cases were 
168 reviewed by two members of the study team. In case of a disagreement, a third review was 
169 performed. IUD insertion and usage in the control group was followed up to one year using the 
170 electronic patient files of the PHC of the City of Helsinki.
171 Outcomes
172 The primary outcome of the study was the number of subsequent TOP during five years of follow-
173 up. As a secondary outcome, we analysed all requested TOPs, including cases of miscarriage, 
174 ectopic pregnancy or blighted ovum, diagnosed at the time of assessment for TOP.
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175 Randomisation and masking
176 Randomisation was performed by using computer-assisted permuted-block method with random 
177 block sizes of four to six. The investigators did not participate in randomisation, which was done 
178 before commencing the study. The group assignments were kept in sealed envelopes, which the 
179 study nurse opened after informing and recruiting the women.
180 Statistical analysis
181 Based on previous studies, a 15% incidence for subsequent abortion during five years was 
182 assumed (Heikinheimo et al., 2008). The power calculation was performed with an assumption 
183 that the intervention would cause a 50% decrease in the incidence of subsequent abortion. By 
184 using the log-rank test, for a power of 80% and a 5% significance level, a total of 350 participants 
185 were needed for each group. To cover for the possible loss-to follow-up, 751 women were 
186 randomised, and finally 748 women were included in the study. (Figure 1)
187 The outcomes were calculated by one thousand follow-up years. The Cox proportional hazards 
188 model was used for calculating hazard ratios (HR). Cumulative subsequent TOPs or requests for 
189 TOP were analysed by using the Kaplan-Meier method with the log-rank test. The Chi-square test 
190 was used as appropriate for categorical variables. To compare distributions between continuous 
191 variables, the Mann-Whitney U-test was used. Statistical analyses were performed with IBM SPSS 
192 Statistics software, version 24 (IBM Corp., Armonk, NY). Statistical significance was defined as 
193 p<0.05. 
194 Role of the funding source
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195 The funders of the study had no role in study design, data collection, data analysis, data interpretation, or 
196 writing of the report. The corresponding author had full access to all the data in the study and had final 
197 responsibility for the decision to submit for publication.
198 Results
199 Of the 2305 eligible women undergoing a first trimester TOP at Kätilöopisto hospital, Department 
200 of Obstetrics and Gynaecology, Helsinki University Hospital, 1139 were interested in intrauterine 
201 contraception, 751 of whom were recruited and randomised between October 18th2010 and 
202 January 21st2013. After randomisation, three women decided to continue with the pregnancy, and 
203 were excluded from the study. Of all the abortions 141 (18.9%) were surgical and 607 (81.1%) 
204 medical.
205 In the intervention group, 301 (80.3%) women received the IUD within four weeks after the 
206 abortion as planned. By three months, 347 (92.5%) women had an IUD inserted. The remaining 28 
207 (7.5%) women did not receive an IUD; 20 (5.3%) women did not attend the follow-up and 8 (2.1%) 
208 declined IUD insertion. 
209 In the control group, 76 (20.4%) women received an IUD at the PHC within three months. 
210 Additionally, 19 (5.1%) women received an IUD at the hospital within three months, either at the 
211 time of surgical abortion or at an additional visit, contrary to the study plan. By one year, a total of 
212 166 (44.5%) women in the control group had an IUD inserted. 
213 The cumulative proportion of women without a subsequent TOP during five years was 89.3% in 
214 the intervention and 83.1% in the control group (p=0.010). The cumulative proportions of women 
215 without a request for subsequent TOP were 87.7% and 82.3% (p=0.028), respectively (Figure 2).
216 During the 5-year follow-up, 40 (10.7%) women in the intervention and 63 (16.9%) in the control 
217 group underwent at least one subsequent induced abortion (HR 1.67 [CI 95% 1.13 to 2.49], 
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218 p=0.011) (Table 2). Altogether 16 (2.1%) women (9 in the intervention and 7 in the control group) 
219 had more than one subsequent TOP during the 5-year follow-up. The overall numbers of 
220 subsequent induced abortions were 50 in the intervention and 72 in the control group, resulting in 
221 an incidence of 26.7 vs. 38.6/1000 years of follow-up (p=0.027). 
222 In the intervention group, 36 (11.8%) of the women undergoing a subsequent TOP had a medical 
223 and 4 (5.8%) a surgical index TOP, whereas in the control group the numbers were 49 (16.4%) and 
224 14 (18.9%), respectively.  The method of abortion did not explain the risk for subsequent TOP in 
225 either group (intervention group: HR 0.46 [CI 95% 0.16 to 1.34], p=0.156; control group: HR 1.19 
226 [CI 95% 0.62 to 2.30], p= 0.603).
227 The total number of women requesting termination of a subsequent unwanted pregnancy 
228 (including cases of miscarriage, ectopic pregnancy and blighted ovum diagnosed at the time of 
229 assessment for TOP) was 46 (12.3%) in the intervention and 66 (17.7%) in the control group (HR 
230 1.52 [CI 95% 1.04 to 2.22], p=0.029). There were 58 requests for TOP in the intervention and 76 in 
231 the control group (30.9 vs. 40.8/1000 years of follow-up, p=0.080). 
232 The median time interval between the index TOP and the first subsequent TOP was 792 days (2.17 
233 years [IQR 604–1439 days/1.65–3.94 years]) in the intervention, and 645 days (1.77 years [IQR 
234 337–1076 days/0.92–2.94 years]) in the control group (p=0.013).
235 When looking at subsequent TOPs during the first three years, a significant difference between the 
236 groups was seen; the number of women undergoing one or several TOP(s) was 23 (6.1%) in the 
237 intervention and 48 (12.9%) in the control group (HR 1.71 [CI 95% 1.04 to 2.81], p=0.035). During 
238 fourth and fifth year, 17 (4.5%) women in the intervention and 15 (4.0%) in the control group had 
239 their first subsequent TOP (HR 1.19 [CI 95% 0.58 to 2.43, p=0.631]. 
240 The number of women requesting a subsequent TOP during the first three years was 27 (7.2%) in 
241 the intervention and 52 (13.9%) in the control group (HR 2.02 [CI 95% 1.27 to 3.22], p=0.003), and 
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242 during the fourth and fifth year, 19 (5.1%) and 14 (3.8%), respectively (HR 0.80 [CI95% 0.40 to 
243 1.59], p=0.523). Altogether 25 TOPs were performed in the intervention group and 52 in the 
244 control group (p=0.001) during the first three years resulting in an incidence of 22.2 vs. 46.5/1000 
245 years of follow-up. However, during the 4th and 5th year there were slightly more TOPs in the 
246 intervention (25) than in the control group (20) (33.3 vs. 26.8/1000, p=0.453). Similarly, the 
247 number of all requested TOPs was 30 vs. 56 (24.0 vs. 46.5/1000, p=0.003) during the first three 
248 years, and 28 vs. 20 (25.3 vs. 18.8/1000, p=0.240) during the 4th and 5th year. 
249 There were no cases of pregnancy during IUD use. Two women in the intervention group had an 
250 unwanted pregnancy due to an unnoticed expulsion of the LNG-IUS; one attended the follow-up 
251 visits at three months and one year, when the IUD was found to be in situ. The other one reported 
252 IUD use at one year but did not attend the 1-year visit. 
253 Based on self-reporting, information collected at the follow-up visits or based on the PHC database 
254 of the City of Helsinki, 228 (60.8%) women in the intervention group and 100 (26.8%) women in 
255 the control group were known to be currently using IUD at one year. Data on the contraceptive 
256 method used at one year were unavailable for 118 (31.5%) women in the intervention and 192 
257 (51.5%) in the control group. Based on these data, the 1-year continuation rate of IUD use in the 
258 intervention group was at least 65.7%, but considering the missing data, possibly considerably 
259 higher. In the intervention group, 225 (60.0%) women attended the 1-year follow-up, and 202 
260 (89.8%) of them were using IUD at that time. In the control group, the corresponding figures were 
261 significantly lower, i.e. 152 (41.4%, p<0.001) and 89 (58.6%, p<0.001). 
262 The risk for subsequent TOP could not be predicted by smoking (HR 1.29 [0.85 to 1.96], p=0.225), 
263 parity (1.16 [0.77 to 1.74], p=0.488), or history of TOP (0.96 [0.64 to 1.42], p=0.827).
264
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265 Discussion
266 We find that provision of intrauterine contraception as part of abortion service was effective in 
267 reducing both the number of women requesting subsequent TOP as well as the overall number of 
268 TOPs. The efficacy of IUD in reducing the need of abortion was limited to the first three years after 
269 the index TOP.
270 The overall rate of subsequent TOP was 14%, which is in line with previous studies as well as the 
271 estimates on which the power calculations of the study were based. The total number of 
272 subsequent TOPs was reduced by approximately one third during the 5-year follow-up due to the 
273 intervention. This is slightly less than the presumed 50% reduction used in the power calculations. 
274 However, these figures were derived from studies comparing IUD vs. non-IUD contraception 
275 (Heikinheimo et al., 2008). We found no predictive background factors for the risk of subsequent 
276 TOP. Thus, the difference in the rate of subsequent abortion between the two study groups is 
277 most likely due to their different rate of IUD use. For example, 93% of the intervention but only 
278 26% of the control group had received the IUD by three months after the abortion (Pohjoranta et 
279 al., 2018). The reasons for this are likely to involve factors related both to the individuals as well as 
280 to the service provision system separating abortion care from pre- and post-abortion 
281 contraceptive care (Duodecim, 2013). Nevertheless, it is noteworthy that even among women who 
282 are highly motivated for intrauterine contraception, providing the service as part of abortion care 
283 makes a significant difference in IUD uptake and the need for future abortion.
284 The randomised study setting with a relatively large sample is a strength. The data on subsequent 
285 TOPs was obtained from the national abortion register, which is of exceptionally high quality and 
286 coverage. In 2011, the coverage of the register was 97% (Heino et al., 2018). In our study data, 
287 only one recurrent TOP identified in the hospital database was missing from the register data.
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288 Both medical and surgical abortions, with different time points of IUD provision, were included. 
289 This may be considered a weakness. However, use of both methods of abortion also reflects the 
290 contemporary practice of TOP. Moreover, significant reduction in the need of subsequent TOP was 
291 seen following both medical and surgical – and thus different means of IUD provision – index 
292 abortion. In addition, due to poor attendance at follow-up and low response rates to the 
293 questionnaires, especially in the control group, reliable information about IUD usage during the 5-
294 year follow-up was unavailable. 
295 The study participants were residents of the City of Helsinki, which may limit the generalizability of 
296 the results. Also, the study population represents women often in an evolving phase of life, and 
297 during the follow-up some of the participants have moved inside Finland or even abroad. Thus, we 
298 were unable to receive comprehensive information concerning the contraceptive methods used 
299 during the follow-up. However, the data derived from the national abortion register cover all TOPs 
300 performed in Finland. Unfortunately, we had no possibility to obtain data on possible subsequent 
301 TOPs performed abroad.
302 It is noteworthy that the effect of intervention was significant during the first 3 years after the 
303 index TOP. However, both the number of women requesting subsequent TOP and the overall 
304 number of TOPs were approximately similar in both groups during the 4th and 5th year after the 
305 index abortion. This is likely explained by discontinuation of IUD use before the follow-up was 
306 complete. 
307 The average age at first delivery in Finland is 29.2 years, whereas the median age of the study 
308 participants at baseline was 27 years (THL, 2017). Thus, it is likely that many of the participants 
309 had planned pregnancies during the five-year follow-up period. Our previous study also supports 
310 this; the mean time from abortion to next pregnancy resulting in delivery was three years 
311 (Heikinheimo et al., 2009). Thus, the effect of the intervention in reducing requested TOPs 
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312 dissolved three years after the index abortion. The cost-effectiveness of this intervention is yet to 
313 be shown, however in large populations, the provision of IUD post abortion has shown to be cost 
314 effective in lowering the number of induced abortions (Ames et al., 2012).
315 A key finding of the study is that the higher incidence of subsequent TOP in the control group was 
316 associated with lower uptake of IUD. Besides the randomisation group, few risk factors for not 
317 having the IUD inserted could be identified in our previous analysis (Pohjoranta et al. 2018). Thus, 
318 in abortion care, in order to optimize the high efficacy of IUD in post-abortion contraception, 
319 integration of counselling, easy-access service, and early and effective IUD provision is important. 
320  
321 Data sharing
322 • Deidentified participant data, study protocol, statistical analysis plan and study protocol will be 
323 made available.
324  • These data will be available 6–36 months after publication for investigators whose proposed use 
325 of the data has been approved by an independent review committee (“learned intermediary”) 
326 identified for this purpose.
327  • Proposals should be directed to oskari.heikinheimo@helsinki.fi.
328
329 Patient and Public Involvement
330
331 This research was done without patient involvement.  Patients were not invited to comment on 
332 the study design and were not consulted to develop patient relevant outcomes or interpret the 
333 results. Patients were not invited to contribute to the writing or editing of this document for 
334 readability or accuracy.
335
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479 Figure 1. Study flow chart.
480 Figure 2. Cumulative proportions of women without subsequent TOP or requested TOP during 
481 five-year follow-up.
482 Figure 3A. Annual rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).
483 Figure 3B. Average rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).
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22 Abstract 
23 Study question: Can the incidence of subsequent termination of pregnancy (TOP) be diminished 
24 by providing intrauterine contraception as part of abortion services?
25 Summary answer: Provision of IUD as part of TOP services reduced the need for subsequent TOP 
26 during 5-year follow-up, but the effect was limited to the first three years.
27 What is known already: IUD is highly effective in preventing subsequent TOP. Prompt initiation 
28 of IUD leads to higher usage rate during follow-up, as compliance with post-TOP IUD insertion 
29 visits is low.
30 Study design, size, duration: The objective of this randomised controlled trial was to assess the 
31 effect of early comprehensive provision of intrauterine contraception after TOP on the incidence 
32 of subsequent TOP during five years of follow-up.
33 This study was conducted at Helsinki University Hospital between October 18th 2010 and January 
34 21st 2013. Altogether 748 women undergoing a first trimester TOP were recruited and randomised 
35 into two groups. The intervention group (n=375) was provided with an IUD during surgical TOP or 
36 1–4 weeks following medical TOP at the hospital providing the abortion care. Women in the 
37 control group (n=373) were advised to contact primary health care for follow-up and IUD 
38 insertion. Subsequent TOPs during the 5-year follow-up were identified from the Finnish Register 
39 on induced abortions. 
40 Participants, setting, methods: The inclusion criteria were age ≥ 18 years, duration of gestation 
41 ≤12 weeks, residence in Helsinki and accepting intrauterine contraception. Women with 
42 contraindications to IUD were excluded.  
43 Main results and the role of chance: The overall numbers of subsequent TOPs were 50 in the 
44 intervention and 72 in the control group (26.7 vs. 38.6/1000 years of follow-up, p=0.027) and 
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45 those of requested TOPs including TOPS and early pregnancy failures 58 and 76 (30.9 vs. 
46 40.8/1000, p=0.080). Altogether 40 (10.7%) women in the intervention and 63 (16.9%) in the 
47 control group underwent one or several subsequent TOPs (HR 1.67 [CI 95% 1.13 to 2.49], 
48 p=0.011). The number of TOPs was reduced by the intervention during years 0–3 (22.2 vs. 
49 46.5/1000, p=0.035), but not during years 4–5 (33.3 vs. 26.8/1000, p=0.631). 
50 Limitations, reasons for caution: Both medical and surgical TOP were used. This may be seen as 
51 a limitation, but it also reflects the contemporary praxis of abortion care. The immediate post-TOP 
52 care were provided by two different organizations allowing us to compare two different ways of 
53 contraceptive service provision following TOP. 
54 Wider implications of the findings: Providing TOP and IUD insertion comprehensively in a same 
55 heath care unit leads to significantly higher rates of attendance, IUD use and significantly lower 
56 risk of subsequent TOP (HR 1.67 [CI 95% 1.13 to 2.49], p=0.011).
57 Study funding/competing interest(s): This study was supported by Helsinki University Central 
58 Hospital Research funds and by research grants provided by the Jenny and Antti Wihuri 
59 Foundation, the Yrjö Jahnsson Foundation, and Finska Läkaresällskapet. EP has received a personal 
60 research grant from the Finnish Medical Society. The City of Helsinki supported the study by 
61 providing the IUDs. The funding organisations had no role in planning or execution of the study, or 
62 in analysing the study results.
63 Trial registration number: The trial was registered at clinicaltrials.gov (NCT01223521).
64 Trial registration date: 18th October 2010.
65 Date of first patient’s enrolment: 18th October 2010.
66 Keywords: Abortion/termination of pregnancy, IUD/intrauterine contraception, subsequent TOP
67
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89 The efficacy of long-acting reversible contraceptives (LARCs) and, especially, that of intrauterine 
90 devices (IUD) in preventing unwanted pregnancy is well established (Peipert et al., 2012; Winner 
91 et al., 2012; Blumenthal et al., 2011; Secura et al., 2014). According to several recent guidelines, 
92 LARCs have become the recommended method of contraception for women in all age groups 
93 (WHO, 2015; RCOG, 2018).
94 Previous cohort studies have shown that young age, parity, and history of termination of 
95 pregnancy (TOP) are associated with increased risk of subsequent TOP (Heikinheimo et al., 2008). 
96 In addition, contraceptive choices affect the risk of subsequent unwanted pregnancy. In cohort 
97 studies, post-abortal use of IUD has been associated with a 60–70% reduction in the need of 
98 subsequent TOP (Okusanya et al., 2014; Rose et al., 2012). 
99 Regardless of the method of TOP, the resumption of ovarian function occurs rapidly; 80% of 
100 women ovulate within 6 weeks after TOP (Schreiber et al., 2011). In addition, 50% of women 
101 resume sexual activity in two weeks following TOP (Boesen et al., 2004). Thus, in order to prevent 
102 subsequent unwanted pregnancy, immediate initiation of effective contraception is important. In 
103 Finland, contraceptive counselling and planning are routinely included in the TOP process, and 
104 women are advised to initiate contraceptive use immediately. Yet, more than one in three women 
105 undergoing a TOP have a history of one or several previous TOPs.  Similar to several other 
106 countries, this rate has been increasing during the past decade in Finland (THL, 2018; 
107 Socialstyrelsen, 2018; INED, 2012; GOV.UK, 2018).
108 The insertion of IUD at the time of surgical TOP is effective and safe, and results in higher IUD use 
109 during follow-up (Okusanya et al., 2014; WHO, 2012; Sääv et al., 2012; Bednarek et al., 2011). 
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110 However, medical abortion has become the dominant method in several countries during the last 
111 decades (THL, 2018; Socialstyrelsen, 2018; INED, 2012; GOV.UK, 2018). Medical abortion poses 
112 challenges concerning IUD provision since compliance with post-abortion care in the service-
113 delivery systems assessed is often poor (Betstadt et al., 2011; Pohjoranta et al., 2018). Immediate 
114 insertion of an IUD after medical TOP (MTOP) is safe, although it is associated with a higher risk of 
115 partial expulsion (Korjamo et al., 2017). In contrast, IUD provision at approximately one week after 
116 MTOP does not significantly increase the risk of expulsion (Sääv et al., 2012; Shimoni et al., 2011; 
117 Betstadt et al., 2011). As with surgical abortion, the prompt provision of IUD leads to a higher rate 
118 of use and subject satisfaction following MTOP (Sääv et al., 2012).
119 In the present study, we studied the efficacy of routine provision of IUD as part of abortion care in 
120 comparison to the current praxis of prescribing oral contraceptives as a bridging method and 
121 directing women to primary health care (PHC) for IUD insertion. Our primary outcome measure 
122 was the number of subsequent TOPs performed during the 5-year follow-up after the index 
123 abortion. The secondary outcomes were the number of all requested TOPs during the follow-up 
124 (including cases of miscarriage, blighted ovum or ectopic pregnancy) and the timing of subsequent 
125 TOP. Previously, we published the 1-year follow-up results concerning the need for subsequent 
126 TOP, success of early IUD insertion, rates of attendance and IUD use, as well as mental and sexual 
127 well-being (Pohjoranta et al., 2015; Pohjoranta et al., 2017; Pohjoranta et al., 2018; Toffol et al., 
128 2016). In the present study, we report the final 5-year results on the need for subsequent TOP.
129
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130 Methods
131 Study design and participants
132 This study design has been described in detail previously (Pohjoranta et al., 2015). The study was 
133 conducted in collaboration with the Helsinki University Hospital and the City of Helsinki. 
134 The inclusion criteria were age ≥18 years, residence in Helsinki, duration of gestation ≤12+0 weeks, 
135 having a non-foetal indication for the abortion and signing an informed consent form. Women 
136 with uterine anomaly, cervical screening result requiring surgical intervention, or inadequate 
137 language skills in Finnish or Swedish were excluded. Acute liver disease and breast cancer were 
138 contraindications for the levonorgestrel-releasing intrauterine system (LNG-IUS), and copper 
139 allergy, iron deficiency anaemia, and Wilson’s disease for copper intrauterine device (Cu-IUD). The 
140 characteristics of the study participants are presented in Table 1.
141
142 Altogether 751 women were randomised into two groups (Figure 1). Women in the intervention 
143 group (n=375) were provided with an IUD (either the 52mg levonorgestrel-releasing intrauterine 
144 system, LNG-IUS, Mirena® or a Cu-IUD, Nova-T®, both manufactured by Bayer Ag [Turku, Finland] 
145 and hereafter referred as IUD) at the hospital responsible for the abortion care. The IUD was 
146 planned to be inserted at the time of surgical abortion (n=70), or at a follow-up visit performed 1–
147 4 weeks after MTOP (n=305). Women in the control group (n=373 [71 cases of surgical and 302 
148 medical abortion]) were prescribed oral contraceptives and advised to contact their PHC unit for 
149 follow-up and contraceptive services including IUD insertion, according to the current national 
150 guideline on induced abortion (Duodecim, 2013). The subsequent TOPs were analysed on an 
151 intention-to-treat analysis (ITT) to assess the efficacy of the intended intervention.
Page 33 of 53
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
8
152 Procedures
153 All abortions were performed according to the national guideline (Duodecim, 2013). All the index 
154 abortions in this study were performed due to a social indication, or based on the woman’s age of 
155 at least 40 years or having given birth to four or more children, both indications for abortion given 
156 in the Finnish legislation. The participants were advised to contact the hospital in case of 
157 suspected abortion-related adverse events or complications. 
158 According to local guideline of the time, all women were invited for a follow-up at three months 
159 after IUD insertion. For the intervention group, this was performed by study nurse. All women 
160 were provided a follow-up visit by a specialist in obstetrics and gynaecology (SS) at one and five 
161 years at the PHC family planning clinic of the City of Helsinki.  
162 Data on subsequent induced abortions during five years after the index abortion were obtained 
163 from the Finnish Register of Induced Abortions kept by the Finnish Institute for Health and Welfare 
164 (THL). In Finland, reporting all TOPs to THL is mandatory by the law, and thus the coverage of the 
165 register is very high (Heino et al., 2018). These data were complemented with data from the 
166 electronic patient files of the Hospital District of Helsinki and Uusimaa, where also the requested 
167 TOPs later diagnosed as ectopic pregnancies or miscarriages were identified. All cases were 
168 reviewed by two members of the study team. In case of a disagreement, a third review was 
169 performed. IUD insertion and usage in the control group was followed up to one year using the 
170 electronic patient files of the PHC of the City of Helsinki.
171 Outcomes
172 The primary outcome of the study was the number of subsequent TOP during five years of follow-
173 up. As a secondary outcome, we analysed all requested TOPs, including cases of miscarriage, 
174 ectopic pregnancy or blighted ovum, diagnosed at the time of assessment for TOP.
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175 Randomisation and masking
176 Randomisation was performed by using computer-assisted permuted-block method with random 
177 block sizes of four to six. The investigators did not participate in randomisation, which was done 
178 before commencing the study. The group assignments were kept in sealed envelopes, which the 
179 study nurse opened after informing and recruiting the women.
180 Statistical analysis
181 Based on previous studies, a 15% incidence for subsequent abortion during five years was 
182 assumed (Heikinheimo et al., 2008). The power calculation was performed with an assumption 
183 that the intervention would cause a 50% decrease in the incidence of subsequent abortion. By 
184 using the log-rank test, for a power of 80% and a 5% significance level, a total of 350 participants 
185 were needed for each group. To cover for the possible loss-to follow-up, 751 women were 
186 randomised, and finally 748 women were included in the study. (Figure 1)
187 The outcomes were calculated by one thousand follow-up years. The Cox proportional hazards 
188 model was used for calculating hazard ratios (HR). Cumulative subsequent TOPs or requests for 
189 TOP were analysed by using the Kaplan-Meier method with the log-rank test. The Chi-square test 
190 was used as appropriate for categorical variables. To compare distributions between continuous 
191 variables, the Mann-Whitney U-test was used. Statistical analyses were performed with IBM SPSS 
192 Statistics software, version 24 (IBM Corp., Armonk, NY). Statistical significance was defined as 
193 p<0.05. 
194 Role of the funding source
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195 The funders of the study had no role in study design, data collection, data analysis, data interpretation, or 
196 writing of the report. The corresponding author had full access to all the data in the study and had final 
197 responsibility for the decision to submit for publication.
198 Results
199 Of the 2305 eligible women undergoing a first trimester TOP at Kätilöopisto hospital, Department 
200 of Obstetrics and Gynaecology, Helsinki University Hospital, 1139 were interested in intrauterine 
201 contraception, 751 of whom were recruited and randomised between October 18th2010 and 
202 January 21st2013. After randomisation, three women decided to continue with the pregnancy, and 
203 were excluded from the study. Of all the abortions 141 (18.9%) were surgical and 607 (81.1%) 
204 medical.
205 In the intervention group, 301 (80.3%) women received the IUD within four weeks after the 
206 abortion as planned. By three months, 347 (92.5%) women had an IUD inserted. The remaining 28 
207 (7.5%) women did not receive an IUD; 20 (5.3%) women did not attend the follow-up and 8 (2.1%) 
208 declined IUD insertion. 
209 In the control group, 76 (20.4%) women received an IUD at the PHC within three months. 
210 Additionally, 19 (5.1%) women received an IUD at the hospital within three months, either at the 
211 time of surgical abortion or at an additional visit, contrary to the study plan. By one year, a total of 
212 166 (44.5%) women in the control group had an IUD inserted. 
213 The cumulative proportion of women without a subsequent TOP during five years was 89.3% in 
214 the intervention and 83.1% in the control group (p=0.010). The cumulative proportions of women 
215 without a request for subsequent TOP were 87.7% and 82.3% (p=0.028), respectively (Figure 2).
216 During the 5-year follow-up, 40 (10.7%) women in the intervention and 63 (16.9%) in the control 
217 group underwent at least one subsequent induced abortion (HR 1.67 [CI 95% 1.13 to 2.49], 
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218 p=0.011) (Table 2). Altogether 16 (2.1%) women (9 in the intervention and 7 in the control group) 
219 had more than one subsequent TOP during the 5-year follow-up. The overall numbers of 
220 subsequent induced abortions were 50 in the intervention and 72 in the control group, resulting in 
221 an incidence of 26.7 vs. 38.6/1000 years of follow-up (p=0.027). 
222 In the intervention group, 36 (11.8%) of the women undergoing a subsequent TOP had a medical 
223 and 4 (5.8%) a surgical index TOP, whereas in the control group the numbers were 49 (16.4%) and 
224 14 (18.9%), respectively.  The method of abortion did not explain the risk for subsequent TOP in 
225 either group (intervention group: HR 0.46 [CI 95% 0.16 to 1.34], p=0.156; control group: HR 1.19 
226 [CI 95% 0.62 to 2.30], p= 0.603).
227 The total number of women requesting termination of a subsequent unwanted pregnancy 
228 (including cases of miscarriage, ectopic pregnancy and blighted ovum diagnosed at the time of 
229 assessment for TOP) was 46 (12.3%) in the intervention and 66 (17.7%) in the control group (HR 
230 1.52 [CI 95% 1.04 to 2.22], p=0.029). There were 58 requests for TOP in the intervention and 76 in 
231 the control group (30.9 vs. 40.8/1000 years of follow-up, p=0.080). 
232 The median time interval between the index TOP and the first subsequent TOP was 792 days (2.17 
233 years [IQR 604–1439 days/1.65–3.94 years]) in the intervention, and 645 days (1.77 years [IQR 
234 337–1076 days/0.92–2.94 years]) in the control group (p=0.013).
235 When looking at subsequent TOPs during the first three years, a significant difference between the 
236 groups was seen; the number of women undergoing one or several TOP(s) was 23 (6.1%) in the 
237 intervention and 48 (12.9%) in the control group (HR 1.71 [CI 95% 1.04 to 2.81], p=0.035). During 
238 fourth and fifth year, 17 (4.5%) women in the intervention and 15 (4.0%) in the control group had 
239 their first subsequent TOP (HR 1.19 [CI 95% 0.58 to 2.43, p=0.631]. 
240 The number of women requesting a subsequent TOP during the first three years was 27 (7.2%) in 
241 the intervention and 52 (13.9%) in the control group (HR 2.02 [CI 95% 1.27 to 3.22], p=0.003), and 
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242 during the fourth and fifth year, 19 (5.1%) and 14 (3.8%), respectively (HR 0.80 [CI95% 0.40 to 
243 1.59], p=0.523). Altogether 25 TOPs were performed in the intervention group and 52 in the 
244 control group (p=0.001) during the first three years resulting in an incidence of 22.2 vs. 46.5/1000 
245 years of follow-up. However, during the 4th and 5th year there were slightly more TOPs in the 
246 intervention (25) than in the control group (20) (33.3 vs. 26.8/1000, p=0.453). Similarly, the 
247 number of all requested TOPs was 30 vs. 56 (24.0 vs. 46.5/1000, p=0.003) during the first three 
248 years, and 28 vs. 20 (25.3 vs. 18.8/1000, p=0.240) during the 4th and 5th year. 
249 There were no cases of pregnancy during IUD use. Two women in the intervention group had an 
250 unwanted pregnancy due to an unnoticed expulsion of the LNG-IUS; one attended the follow-up 
251 visits at three months and one year, when the IUD was found to be in situ. The other one reported 
252 IUD use at one year but did not attend the 1-year visit. 
253 Based on self-reporting, information collected at the follow-up visits or based on the PHC database 
254 of the City of Helsinki, 228 (60.8%) women in the intervention group and 100 (26.8%) women in 
255 the control group were known to be currently using IUD at one year. Data on the contraceptive 
256 method used at one year were unavailable for 118 (31.5%) women in the intervention and 192 
257 (51.5%) in the control group. Based on these data, the 1-year continuation rate of IUD use in the 
258 intervention group was at least 65.7%, but considering the missing data, possibly considerably 
259 higher. In the intervention group, 225 (60.0%) women attended the 1-year follow-up, and 202 
260 (89.8%) of them were using IUD at that time. In the control group, the corresponding figures were 
261 significantly lower, i.e. 152 (41.4%, p<0.001) and 89 (58.6%, p<0.001). 
262 The risk for subsequent TOP could not be predicted by smoking (HR 1.29 [0.85 to 1.96], p=0.225), 
263 parity (1.16 [0.77 to 1.74], p=0.488), or history of TOP (0.96 [0.64 to 1.42], p=0.827).
264
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265 Discussion
266 We find that provision of intrauterine contraception as part of abortion service was effective in 
267 reducing both the number of women requesting subsequent TOP as well as the overall number of 
268 TOPs. The efficacy of IUD in reducing the need of abortion was limited to the first three years after 
269 the index TOP.
270 The overall rate of subsequent TOP was 14%, which is in line with previous studies as well as the 
271 estimates on which the power calculations of the study were based. The total number of 
272 subsequent TOPs was reduced by approximately one third during the 5-year follow-up due to the 
273 intervention. This is slightly less than the presumed 50% reduction used in the power calculations. 
274 However, these figures were derived from studies comparing IUD vs. non-IUD contraception 
275 (Heikinheimo et al., 2008). We found no predictive background factors for the risk of subsequent 
276 TOP. Thus, the difference in the rate of subsequent abortion between the two study groups is 
277 most likely due to their different rate of IUD use. For example, 93% of the intervention but only 
278 26% of the control group had received the IUD by three months after the abortion (Pohjoranta et 
279 al., 2018). The reasons for this are likely to involve factors related both to the individuals as well as 
280 to the service provision system separating abortion care from pre- and post-abortion 
281 contraceptive care (Duodecim, 2013). Nevertheless, it is noteworthy that even among women who 
282 are highly motivated for intrauterine contraception, providing the service as part of abortion care 
283 makes a significant difference in IUD uptake and the need for future abortion.
284 The randomised study setting with a relatively large sample is a strength. The data on subsequent 
285 TOPs was obtained from the national abortion register, which is of exceptionally high quality and 
286 coverage. In 2011, the coverage of the register was 97% (Heino et al., 2018). In our study data, 
287 only one recurrent TOP identified in the hospital database was missing from the register data.
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288 Both medical and surgical abortions, with different time points of IUD provision, were included. 
289 This may be considered a weakness. However, use of both methods of abortion also reflects the 
290 contemporary practice of TOP. Moreover, significant reduction in the need of subsequent TOP was 
291 seen following both medical and surgical – and thus different means of IUD provision – index 
292 abortion. In addition, due to poor attendance at follow-up and low response rates to the 
293 questionnaires, especially in the control group, reliable information about IUD usage during the 5-
294 year follow-up was unavailable. 
295 The study participants were residents of the City of Helsinki, which may limit the generalizability of 
296 the results. Also, the study population represents women often in an evolving phase of life, and 
297 during the follow-up some of the participants have moved inside Finland or even abroad. Thus, we 
298 were unable to receive comprehensive information concerning the contraceptive methods used 
299 during the follow-up. However, the data derived from the national abortion register cover all TOPs 
300 performed in Finland. Unfortunately, we had no possibility to obtain data on possible subsequent 
301 TOPs performed abroad.
302 It is noteworthy that the effect of intervention was significant during the first 3 years after the 
303 index TOP. However, both the number of women requesting subsequent TOP and the overall 
304 number of TOPs were approximately similar in both groups during the 4th and 5th year after the 
305 index abortion. This is likely explained by discontinuation of IUD use before the follow-up was 
306 complete. 
307 The average age at first delivery in Finland is 29.2 years, whereas the median age of the study 
308 participants at baseline was 27 years (THL, 2017). Thus, it is likely that many of the participants 
309 had planned pregnancies during the five-year follow-up period. Our previous study also supports 
310 this; the mean time from abortion to next pregnancy resulting in delivery was three years 
311 (Heikinheimo et al., 2009). Thus, the effect of the intervention in reducing requested TOPs 
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312 dissolved three years after the index abortion. The cost-effectiveness of this intervention is yet to 
313 be shown, however in large populations, the provision of IUD post abortion has shown to be cost 
314 effective in lowering the number of induced abortions (Ames et al., 2012).
315 A key finding of the study is that the higher incidence of subsequent TOP in the control group was 
316 associated with lower uptake of IUD. Besides the randomisation group, few risk factors for not 
317 having the IUD inserted could be identified in our previous analysis (Pohjoranta et al. 2018). Thus, 
318 in abortion care, in order to optimize the high efficacy of IUD in post-abortion contraception, 
319 integration of counselling, easy-access service, and early and effective IUD provision is important. 
320  
321 Data sharing
322 • Deidentified participant data, study protocol, statistical analysis plan and study protocol will be 
323 made available.
324  • These data will be available 6–36 months after publication for investigators whose proposed use 
325 of the data has been approved by an independent review committee (“learned intermediary”) 
326 identified for this purpose.
327  • Proposals should be directed to oskari.heikinheimo@helsinki.fi.
328
329 Patient and Public Involvement
330
331 This research was done without patient involvement.  Patients were not invited to comment on 
332 the study design and were not consulted to develop patient relevant outcomes or interpret the 
333 results. Patients were not invited to contribute to the writing or editing of this document for 
334 readability or accuracy.
335
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479 Figure 1. Study flow chart.
480 Figure 2. Cumulative proportions of women without subsequent TOP or requested TOP during 
481 five-year follow-up.
482 Figure 3A. Annual rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).
483 Figure 3B. Average rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).
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Age (years); median (IQR) 27 (11) 27 (10) 0.489
Marital status 0.157
Single 202 (53.9) 229 (61.4)
Cohabiting 102 (27.2) 92 (24.7)
Married 71 (18.9) 52 (13.9)
Regular smoking 188 (50.1) 189 (51.4) 0.710
Regular use of alcohol 275 (73.3) 286 (77.9) 0.145
Contraceptive method 




45 (12.0) 49 (13.1)
Progestin-only pill 12 (3.2) 9 (2.4)
Cu-IUD – 1 (0.3)
Condom 159 (42.4) 135 (36.2)
Other 8 (2.1) 14 (3.8)
None 151 (40.3) 165 (44.2)
History of delivery 187 (49.9) 175 (46.9) 0.501
History of TOP 174 (46.4) 153 (41.0) 0.095
Method of abortion
Surgical 69 (18.4) 74 (19.8) 0.617
Medical 306 (81.6) 299 (80.2)
Duration of index 
pregnancy (days); median 
(IQR)
57 (17) 56 (16) 0.208
* Combined oral contraceptive pill, patch or ring
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40 (10.7) 63 (16.9) 1.67 (1.13–2.49) 0.011*
Women with 
requested TOP(s)

















* Log rank test
** Chi square test
*** Number of TOP/1000 years of follow-up
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Intervention group    
     Subsequent TOP 375 369 352 343
     Requested TOP 375 367 349 338
Control group    
     Subsequent TOP 373 352 329 316
     Requested TOP 373 350 325 313
Subsequent TOP: HR 1.67 (CI 95% 1.13–2.49); p=0.011.
Requested TOP: HR 1.52 (CI 95% 1.04–2.22); p=0.029.
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Figure 3A. Rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).








Intervention group Control group
Figure 3B. Average rate of subsequent TOP during five-year follow-up (/1000 years of follow-up).












Intervention group Control group
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